title: Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer.
abstract: BACKGROUND
  Bevacizumab plus taxane chemotherapy improves progression-free survival (PFS) versus taxane monotherapy in the first-line treatment of HER2-negative metastatic breast cancer (MBC) and appears promising in the second-line setting. This retrospective analysis evaluated the efficacy and safety of this combination in a real-world setting.
  
  
  METHODS
  Eligible patients received bevacizumab (10 mg/kg days 1 and 15, every 28 days) plus paclitaxel (80 mg/m(2) days 1, 8, and 15, every 28 days) as first-line therapy for MBC, or as subsequent lines, including bevacizumab continuation therapy, at La Paz University Hospital between August 2007 and October 2012. End points included objective response rate (ORR), PFS, overall survival (OS), and safety.
  
  
  RESULTS
  Seventy-eight patients were included. Median PFS was 12.8 months for patients receiving first-line treatment and 9.3 months for subsequent lines. Forty-five patients (57.7%) continued bevacizumab after stopping paclitaxel, and had significantly longer PFS and OS than those who did not (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.248-0.653, P<0.001; HR 0.39, 95% CI 0.218-0.710, P=0.002; respectively). In the continuation phase, estrogen receptor-positive patients had longer PFS and OS when receiving hormone therapy plus bevacizumab versus patients receiving only bevacizumab (HR 0.50, 95% CI 0.24-1.04, P=0.06; HR 0.43, 95% CI 0.16-1.16, P=0.09; respectively). Thirty-five patients (44.9%) reported grade 3-4 adverse events.
  
  
  CONCLUSIONS
  Bevacizumab plus paclitaxel was effective in HER2-negative MBC. Continuation of bevacizumab and addition of hormone therapy following paclitaxel therapy could be beneficial.
authors.affiliation: Medical Oncology Department, University Hospital La Paz (IdiPAZ), Madrid, Spain.
authors.forename: Andrés
authors.initials: A
authors.lastname: Redondo
authors.affiliation: Medical Oncology Department, University Hospital La Paz (IdiPAZ), Madrid, Spain.
authors.forename: Virginia
authors.initials: V
authors.lastname: Martínez
authors.affiliation: Medical Oncology Department, University Hospital La Paz (IdiPAZ), Madrid, Spain.
authors.forename: Pilar
authors.initials: P
authors.lastname: Zamora
authors.affiliation: Medical Oncology Department, University Hospital La Paz (IdiPAZ), Madrid, Spain.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Castelo
authors.affiliation: Medical Oncology Department, University Hospital La Paz (IdiPAZ), Madrid, Spain.
authors.forename: Alvaro
authors.initials: A
authors.lastname: Pinto
authors.affiliation: Medical Oncology Department, University Hospital La Paz (IdiPAZ), Madrid, Spain.
authors.forename: Patricia
authors.initials: P
authors.lastname: Cruz
authors.affiliation: Medical Oncology Department, University Hospital La Paz (IdiPAZ), Madrid, Spain.
authors.forename: Oliver
authors.initials: O
authors.lastname: Higuera
authors.affiliation: Translational Oncology and Molecular Pathology Laboratory, University Hospital La Paz (IdiPAZ), Madrid, Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: Mendiola
authors.affiliation: Pathology Department, University Hospital La Paz (IdiPAZ), Madrid, Spain.
authors.forename: David
authors.initials: D
authors.lastname: Hardisson
authors.affiliation: Medical Oncology Department, University Hospital La Paz (IdiPAZ), Madrid, Spain.
authors.forename: Enrique
authors.initials: E
authors.lastname: Espinosa
keywords: advanced breast cancer; bevacizumab; first line; hormone therapy; maintenance